Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07617805 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC

Name: EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC — clinical trial record (NCT07617805)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DUAL-HN

StatusRecruiting

PhasePhase 1/2

SponsorBeijing Biotech

Started2026-03-02

View on ClinicalTrials.gov ↗

Beijing Biotech

32 trials monitored

See all monitored trials

Head & Neck Cancer

2,051 trials monitored

See 116 trials at risk

This example Phase 1/2 protocol evaluates allogeneic EGFR/HER2 dual-target CAR-NK cells in adults with recurrent or metastatic HNSCC whose tumors meet protocol-defined co-expression criteria for EGFR and HER2/ERBB2. The study is designed as a biomarker-enriched, open-label, non-randomized trial with a dose-escalation safety lead-in followed by an expansion cohort at the recommended Phase 2 dose (RP2D).

Trial Details

NCT Number	NCT07617805
Lead Sponsor	Beijing Biotech
Conditions	Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Biomarker-positive EGFR/HER2- Expressing HNSCC
Enrollment	42 participants
Start Date	2026-03-02
Primary Completion	2027-03-14 (estimated)
Study Completion	2028-05-17 (estimated)
Updated on ClinicalTrials.gov	2026-06-01